Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Venetoclax in R/R MM patients

Nina Shah • 8 Jun 2020
EHA 2020
Multiple Myeloma Venetoclax
BELLINI

Nina Shah, MD, of the University of California, San Francisco, CA, outlines the use of venetoclax in relapsed/refractory (R/R) multiple myeloma patients, highlighting the BELLINI trial (NCT02755597). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nina Shah

19:39
T-Cell Engagers: targets, challenges and opportunity
Hermann Einsele et al. • 27 Mar 2022
1:28
NKTR-255 in multiple myeloma and NHL
Nina Shah • 10 Dec 2021
2:15
Reporting patient experiences during the KarMMa trial
Nina Shah • 10 Dec 2021
2:06
Subanalysis of the KarMMa Trial: Predicting complete response to CAR-T in multiple myeloma
Nina Shah • 10 Dec 2021

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals